Incretin & metabolic research compounds
Cagrilintide
Also known as CagriSema (with semaglutide)
A long-acting amylin analogue, studied alone and in a fixed combination with semaglutide (CagriSema).
In 60 seconds
Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination.
- A phase 2 dose-finding trial measured cagrilintide’s dose–response on body weight, safety and tolerability.
- A phase 3 trial measured weight change with the cagrilintide–semaglutide combination (CagriSema).
- A phase 3 trial of CagriSema in adults with type 2 diabetes.
Mechanism
Amylin is a pancreatic hormone co-secreted with insulin that induces satiety and slows gastric emptying. Cagrilintide is a lipidated, long-acting analogue acting at amylin (and calcitonin) receptors, complementing GLP-1 receptor agonism.
Research status
Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Not yet approved.
Key studies
A phase 2 dose-finding trial measured cagrilintide’s dose–response on body weight, safety and tolerability.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial — Lancet, 2021 · PMID 34798060
A phase 3 trial measured weight change with the cagrilintide–semaglutide combination (CagriSema).
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity — N Engl J Med, 2025 · PMID 40544433
A phase 3 trial of CagriSema in adults with type 2 diabetes.
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes — N Engl J Med, 2025 · PMID 40544432
A phase 1b trial characterised the safety and pharmacokinetics of combining cagrilintide with semaglutide.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial — Lancet, 2021 · PMID 33894838
Safety signals in the literature
Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination.
Legal status (South Africa)
Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Cagrilintide and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Cagrilintide
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Cagrilintide?
A long-acting amylin analogue, studied alone and in a fixed combination with semaglutide (CagriSema). Amylin is a pancreatic hormone co-secreted with insulin that induces satiety and slows gastric emptying. Cagrilintide is a lipidated, long-acting analogue acting at amylin (and calcitonin) receptors, complementing GLP-1 receptor agonism.
What is the research status of Cagrilintide?
Phase 2 monotherapy data (2021) and phase 3 combination trials with semaglutide (REDEFINE, 2025–2026). Not yet approved.
What safety signals are reported for Cagrilintide?
Trials report the gastrointestinal profile expected of the incretin/amylin class; the phase 1b study characterised tolerability of the combination.
Does Living Water Labs stock Cagrilintide?
Not at present. Cagrilintide is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
More in Incretin & metabolic
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
